Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Olomorasib was put through its paces in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) in the phase 1/2 LOXO-RAS-20001 study, which included 17 previously untreated patients.

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

In the phase III study, ivonescimab achieved a median PFS of 11.14 months compared with 5.82 months with pembrolizumab, translating into a 49% reduction in the risk of progression or death (HR 0. ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...